DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on January 13, 2006; DOI: 10.1124/dmd.105.007625

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.007625v1
34/4/534    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marechal, J.-D.
Right arrow Articles by Sutcliffe, M. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marechal, J.-D.
Right arrow Articles by Sutcliffe, M. J


Received for publication September 29, 2005.
Revised January 6, 2006.
Accepted for publication January 9, 2006.

In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by co-medications commonly used by patients with cancer

Jean-Didier Marechal 1, Jinglei Yu 2, Simon Brown 2, Iouri Kapelioukh 2, Elaine M Rankin 2, C Roland Wolf 2, Gordon CK Roberts 3, Mark JI Paine 2, Michael J Sutcliffe 1*

1 University of Manchester 2 University of Dundee 3 University of Leicester

* Address correspondence to: E-mail: michael.sutcliffe{at}manchester.ac.uk

Abstract

Cytochrome P450 3A4 (CYP3A4) is the major enzyme responsible for phase I drug metabolism of many anti-cancer agents. It is also a major route for metabolism of many drugs used by patients to treat the symptoms caused by cancer and its treatment as well as their other illnesses, for example cardiovascular disease. To assess the ability to inhibit CYP3A4 of drugs most commonly used by our patients during cancer therapy, we have made in silico predictions based on the crystal structures of CYP3A4. From this set of 33 common co-medicated drugs, ten were predicted to be inhibitors of CYP3A4, with the anti-diarrhoeal drug loperamide predicted to be the most potent. There was significant correlation (r2 = 0.75 - 0.66) between predicted affinity and measured IC50 values, and loperamide was confirmed as a potent inhibitor (IC50 of 0.050 ± 0.006 µM). Active site docking studies predicted an orientation of loperamide consistent with formation of the major (N-demethylated) metabolite, where it interacts with the phenylalanine cluster, Arg-212 and Glu-374; experimental evidence for the latter interaction comes from the ~12-fold increase in KM for loperamide observed for the Glu-374-Gln mutant. The commonly prescribed drugs loperamide, amitryptyline, diltiazem, domperidone, lanzoprazole, omeprazole and simvastatin were identified by our in silico and in vitro screens as relatively potent inhibitors of CYP3A4 which have the potential to interact with cytotoxic agents to cause adverse effects, highlighting the likelihood of drug-drug interactions affecting chemotherapy treatment.


Key words: computer modeling and simulation, CYP3A, drug development, drug-drug interactions, human CYP enzymes


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
R. Z. Cer, U. Mudunuri, R. Stephens, and F. J. Lebeda
IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding
Nucleic Acids Res., July 1, 2009; 37(suppl_2): W441 - W445.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
S. C. Armstrong, G. H. Wynn, and N. B. Sandson
Pharmacokinetic Drug Interactions of Synthetic Opiate Analgesics
Psychosomatics, March 1, 2009; 50(2): 169 - 176.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Sun, C. Moore, P. M. Dansette, S. Kumar, J. R. Halpert, and G. S. Yost
Dehydrogenation of the Indoline-Containing Drug 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (Indapamide) by CYP3A4: Correlation with in Silico Predictions
Drug Metab. Dispos., March 1, 2009; 37(3): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Kapelyukh, M. J. I. Paine, J.-D. Marechal, M. J. Sutcliffe, C. R. Wolf, and G. C. K. Roberts
Multiple Substrate Binding by Cytochrome P450 3A4: Estimation of the Number of Bound Substrate Molecules
Drug Metab. Dispos., October 1, 2008; 36(10): 2136 - 2144.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Yasuda, A. Ranade, R. Venkataramanan, S. Strom, J. Chupka, S. Ekins, E. Schuetz, and K. Bachmann
A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine
Drug Metab. Dispos., August 1, 2008; 36(8): 1689 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al.
The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Yu, M. J. I. Paine, J.-D. Marechal, C. A. Kemp, C. J. Ward, S. Brown, M. J. Sutcliffe, G. C. K. Roberts, E. M. Rankin, and C. R. Wolf
IN SILICO PREDICTION OF DRUG BINDING TO CYP2D6: IDENTIFICATION OF A NEW METABOLITE OF METOCLOPRAMIDE
Drug Metab. Dispos., August 1, 2006; 34(8): 1386 - 1392.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.